Become A Featured Company

Psychedelics Then & Now: From Ancient Times to the Psychedelic Renaissance

Ryan Allway

April 14th, 2021

App, Exclusive, Psychedelics, Top Story

Psychedelics have become one of the most promising classes of drugs in a generation, as well as an exciting new industry for investors. Despite their resurgence among researchers and investors, psychedelics have been used for thousands of years before they were criminalized in the 1970s in the United States and around the world.

Let’s take a look at the rich history of psychedelics over thousands of years, the renaissance that has emerged over the past few years and how Tryp Therapeutics (CSE: TRYP, OTCQB: TRYPF) is positioning itself to unlock value through its PFN™ platform and recent patent filings.

A Brief History of Psychedelics

Psychedelics have a long history that began as early as 4,000 B.C. E. where cave paintings were found in Northern Africa and Europe. In 3,700 to 3,660 B.C.E., there’s evidence that peyote was used in ceremonies by indigenous cultures in the Americas. The Aztec’s may have consumed mushrooms, known as the “flash of the Gods” between 1300 and 1521 C.E. while Catholic texts from Europe in 1500 C.E. refer to peyote use as “witchcraft”.

Modern science began in the 1900s with the isolation of mescaline and ibogaine in Europe. Synthetics emerged soon after with the invention of MDMA in 1912 and LSD in 1938. Psilocybin was discovered by Albert Hoffman in 1958 and Calvin Stevens synthesized ketamine in 1962, which ushered in the modern era of psychedelics. Of course, these drugs were regulated around the world between 1962 and 1971, creating a prohibition era.

The psychedelic renaissance began after 1971 as researchers began to discover the potential for psychedelics to treat a range of different medical conditions. After widespread cannabis legalization in the early 2010s, the movement to decriminalize psychedelics—especially for research and medical use—picked up steam. The emergence of funding from venture capital investors helped finance large-scale clinical trials that finally tipped the scale in the 2020s.

Click here to learn more about investing in Tryp Therapeutics

Bringing Psychedelics to Medicine

A growing number of private and public companies have emerged in the late 2010s and early 2020s to develop and commercialize psychedelic treatments for medical conditions. In particular, psychiatric conditions like major depressive disorder and anxiety seem to be greatly enhanced through psychedelic treatments. The breakthroughs have been strong enough to secure Breakthrough Therapy Status for several programs from the U.S. FDA.

Tryp Therapeutics (CSE: TRYP, OTCQB:TRYPF) is a pharmaceutical company with a psilocybin-for-neuropsychiatric disorders, or PFN™, platform. By developing novel synthetic psilocybin, the company aims to power a new class of drugs for the treatment of certain neuropsychiatric disorders. The company’s lead PFN™ drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome with few effective treatments and no cure, and of eating disorders.

The company recently announced that it submitted a provisional patent to improve how psychedelics are administered across a broad range of conditions. In particular, the proprietary methods represent the foundational elements of a comprehensive medical treatment program that the company is developing.  It also marks the first of many patent filings to enhance the effectiveness of psychedelics and build a valuable patent portfolio.

Click here to learn more about investing in Tryp Therapeutics

Looking Ahead

Psychedelics have a rich history spanning thousands of years. While the class of drugs has been restricted for therapeutic use since the 1970s, the psychedelic renaissance has sparked renewed interest and a range of companies seeking to bring therapeutics to market.

Tryp Therapeutics (CSE: TRYP) represents one of the most promising companies in the space with its PFN™ platform and its clinical research programs for fibromyalgia and eating disorders. With its recent provisional patent filing, the company is making core improvements to the formulation, delivery and dosing of active ingredients, helping to differentiate itself from other companies in the space. Investors may want to take a closer look at the stock given these dynamics and its upcoming clinical catalysts.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading